Last $3.27 USD
Change Today -0.07 / -2.10%
Volume 1.1M
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Open
$3.36
Previous Close
$3.34
Day High
$3.36
Day Low
$3.23
52 Week High
07/3/14 - $4.17
52 Week Low
11/6/13 - $1.65
Market Cap
381.5M
Average Volume 10 Days
1.4M
EPS TTM
$-0.57
Shares Outstanding
116.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs include MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration. The Sequenom Bioscience segment provides technology and research use only tools, such as the MassARRAY System platform, chip and reagent consumables, software, and biomarker assay panels for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.

570 Employees
Last Reported Date: 02/27/14
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Scientific and Strategy Officer
Total Annual Compensation: $375.0K
Consultant
Total Annual Compensation: $354.3K
Compensation as of Fiscal Year 2013.

sequenom inc (SQNM) Key Developments

Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation

Sequenom and Isis Innovation have reported that Sequenom has purchased noninvasive prenatal testing intellectual property from Isis Innovation, for $14.55 million, which includes $3.2 million as the final royalty payment due to Isis under the prior agreement and the waiver of $2.1 million in paid legal fees that Isis owed to Sequenom, with additional downstream payments contingent on revenues exceeding certain thresholds. The companies said that under the terms of the agreement, Sequenom is now the owner of global intellectual property for noninvasive prenatal genetic diagnostic testing on paternally inherited fetal nucleic acids derived from maternal plasma or serum. Sequenom previously had exclusive rights to this intellectual property under a licensing agreement with Isis Innovation established in 2005. As part of the purchase agreement, Isis Innovation has rights in certain fields of use.

Sequenom Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:20 AM

Sequenom Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:20 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Carolyn D. Beaver, Chief Financial Officer, Chief Accounting Officer and Vice President, William J. Welch, Chief Executive Officer, President and Director.

Sequenom Enters into License Agreement with Mayo Medical Laboratories

Sequenom Inc. and Mayo Medical Laboratories have announced a license agreement for noninvasive prenatal testing patents and applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $3.27 USD -0.07

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $15.44 USD +0.19
Luminex Corp $19.72 USD +0.25
Pacific Biosciences of California Inc $5.56 USD 0.00
STAAR Surgical Co $10.48 USD -0.36
SurModics Inc $20.64 USD -0.42
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.